Dysregulation of miR-192-5p in acute pancreatitis patients with nonalcoholic fatty liver and its functional role in acute pancreatitis progression.
Adult
Animals
Apoptosis
Case-Control Studies
Cell Line
Cell Proliferation
Cytokines
/ metabolism
Disease Progression
Female
Humans
Inflammation Mediators
/ metabolism
Male
MicroRNAs
/ blood
Middle Aged
Non-alcoholic Fatty Liver Disease
/ complications
Pancreas, Exocrine
/ metabolism
Pancreatitis
/ complications
Rats
Signal Transduction
acute pancreatitis
diagnosis
inflammation
microRNA-192-5p
nonalcoholic fatty liver disease
proliferation
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
29 05 2020
29 05 2020
Historique:
received:
16
12
2019
revised:
06
05
2020
accepted:
11
05
2020
pubmed:
15
5
2020
medline:
24
3
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is a frequent metabolic disease and has been demonstrated to contribute to the severity of acute pancreatitis (AP). The present study aimed to investigate the aberrant expression of microRNA-192-5p (miR-192-5p) in AP patients with NAFLD, and further analyze the clinical significance and biological function of miR-192-5p in AP progression. Expression of miR-192-5p was estimated using quantitative real-time PCR (qRT-PCR). Diagnostic value of miR-192-5p was evaluated by the receiver operating characteristic curve (ROC). The effects of miR-192-5p on cell proliferation, apoptosis and inflammatory response of pancreatic acinar cells were further assessed by CCK-8 assay, flow cytometry and enzyme-linked immunosorbent assay (ELISA). Circulating miR-192-5p was decreased in AP patients with NAFLD compared with those patients without NAFLD and healthy controls (P<0.05). The down-regulated expression of miR-192-5p had a relative high diagnostic accuracy to distinguish the AP patients with NAFLD from the cases without NAFLD. Furthermore, the overexpression of miR-192-5p in pancreatic acinar cells led to the decreased cell proliferation, increased cell apoptosis and suppressed inflammatory reaction (all P<0.05). Collectively, all data indicated that serum expression of miR-192-5p in AP patients with NAFLD is significantly decreased and serves as a candidate diagnostic biomarker. The up-regulation of miR-192-5p in pancreatic acinar cell leads to increased cell apoptosis and decreased inflammatory response, suggesting the potential of miR-192-5p as a therapeutic target of AP.
Sections du résumé
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is a frequent metabolic disease and has been demonstrated to contribute to the severity of acute pancreatitis (AP). The present study aimed to investigate the aberrant expression of microRNA-192-5p (miR-192-5p) in AP patients with NAFLD, and further analyze the clinical significance and biological function of miR-192-5p in AP progression.
METHODS
Expression of miR-192-5p was estimated using quantitative real-time PCR (qRT-PCR). Diagnostic value of miR-192-5p was evaluated by the receiver operating characteristic curve (ROC). The effects of miR-192-5p on cell proliferation, apoptosis and inflammatory response of pancreatic acinar cells were further assessed by CCK-8 assay, flow cytometry and enzyme-linked immunosorbent assay (ELISA).
RESULTS
Circulating miR-192-5p was decreased in AP patients with NAFLD compared with those patients without NAFLD and healthy controls (P<0.05). The down-regulated expression of miR-192-5p had a relative high diagnostic accuracy to distinguish the AP patients with NAFLD from the cases without NAFLD. Furthermore, the overexpression of miR-192-5p in pancreatic acinar cells led to the decreased cell proliferation, increased cell apoptosis and suppressed inflammatory reaction (all P<0.05).
CONCLUSION
Collectively, all data indicated that serum expression of miR-192-5p in AP patients with NAFLD is significantly decreased and serves as a candidate diagnostic biomarker. The up-regulation of miR-192-5p in pancreatic acinar cell leads to increased cell apoptosis and decreased inflammatory response, suggesting the potential of miR-192-5p as a therapeutic target of AP.
Identifiants
pubmed: 32406504
pii: 224146
doi: 10.1042/BSR20194345
pmc: PMC7256679
pii:
doi:
Substances chimiques
Cytokines
0
Inflammation Mediators
0
MIRN192 microRNA, human
0
MIRN192 microRNA, rat
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 The Author(s).
Références
J Cell Biochem. 2019 Sep;120(9):15844-15850
pubmed: 31106896
Am J Pathol. 2017 Dec;187(12):2726-2743
pubmed: 28935577
Hepatology. 2019 Nov 28;:
pubmed: 31782176
Oxid Med Cell Longev. 2018 Sep 30;2018:8515343
pubmed: 30402207
World J Gastroenterol. 2014 Dec 7;20(45):16868-80
pubmed: 25493000
Theranostics. 2015 Jul 13;5(10):1122-43
pubmed: 26199650
Pancreas. 2015 May;44(4):596-601
pubmed: 25760428
Pancreatology. 2019 Jun;19(4):557-565
pubmed: 31122822
Biomed Pharmacother. 2018 Nov;107:1744-1753
pubmed: 30257393
Dis Markers. 2017;2017:7293459
pubmed: 29332987
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(6):378-385
pubmed: 28603209
Oncol Lett. 2018 May;15(5):6947-6956
pubmed: 29731868
Cell Death Dis. 2017 Jul 13;8(7):e2918
pubmed: 28703808
Biochem Biophys Res Commun. 2017 Nov 4;493(1):227-232
pubmed: 28899784
Magn Reson Imaging Clin N Am. 2018 Aug;26(3):439-450
pubmed: 30376980
Methods Mol Biol. 2017;1509:1-10
pubmed: 27826912
Pediatr Obes. 2018 Mar;13(3):175-182
pubmed: 29271122
Am J Med Sci. 2017 Feb;353(2):178-186
pubmed: 28183420
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Sci Rep. 2017 Nov 3;7(1):14493
pubmed: 29101357
Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416
pubmed: 23896955
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018 Oct;34(10):931-936
pubmed: 30554587
Eur J Intern Med. 2017 Mar;38:73-78
pubmed: 27825671
Biomed Res Int. 2019 Jan 22;2019:9583790
pubmed: 30805370
Brief Funct Genomics. 2018 Jul 22;18(4):255-266
pubmed: 30785618
Ther Apher Dial. 2018 Dec;22(6):649-655
pubmed: 29989302
Clin Lab. 2017 Sep 1;63(9):1315-1321
pubmed: 28879701
Gut. 2016 Nov;65(11):1781-1783
pubmed: 27436271
Biomed Pharmacother. 2020 Feb;122:109692
pubmed: 31918268
World J Gastroenterol. 2016 Sep 14;22(34):7660-75
pubmed: 27678349
Clin Radiol. 2016 Feb;71(2):121-33
pubmed: 26602933
World J Gastroenterol. 2017 Dec 14;23(46):8140-8151
pubmed: 29290651